| [1] |
Dillman RO. Cancer immunotherapy [ J]. Cancer Biother Radiopharm,2011,26(1):1-64.
|
| [2] |
Page DB, Naidoo J, McArthur HL. Emerging immunotherapy strategies in breast cancer[J]. Immunotherapy, 2014,6(2):195-209.
|
| [3] |
Bahl S, Roses RE, Sharma A, et al. Asymptomatic changes in cardiac function can occur in ductal carcinoma-in-situ patients following treatment with HER-2/neu-pulsed dendritic cell vaccines [J].Am J Surg,2009,198(4):488-494.
|
| [4] |
Xie Y, Chen Y, Ahmed KA, et al. Potent CD4 + T-cell epitope P30 enhances HER2/neu-engineered dendritic cellinduced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4 + T-cell-stimulated CTL responses[J].Cancer Gene Ther,2013,20(10):590-598.
|
| [5] |
Zheng X, Koropatnick J, Chen D, et al. Silencing IDO in dendritic cells: a novel approach to enhance cancer immunotherapy in a murine breast cancer model[J]. Int J Cancer,2013,132(4):967-977.
|
| [6] |
Ge Y, Xi H, Ju S, et al. Blockade of PD-1/PD-L1 immune checkpoint during DC vaccination induces potent protective immunity against breast cancer in hu-SCID mice[J]. Cancer Lett,2013,336(2):253-259.
|
| [7] |
Baek S, Kim CS, Kim SB, et al. Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase Ⅰ/Ⅱtrial[J].J Transl Med,2011,9:178.
|
| [8] |
Hafid SR, Radhakrishnan AK, Nesaretnam K. Tocotrienols are good adjuvants for developing cancer vaccines [ J]. BMC Cancer,2010,10:5.
|
| [9] |
Hamilton E,Blackwell K,Hobeika AC,et al. Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition[J].J Transl Med,2012,10:28.
|
| [10] |
Gritzapis AD, Fridman A, Perez SA, et al. HER-2/neu (657-665) represents an immunogenic epitope of HER-2/neu oncoprotein with potent antitumor properties [J]. Vaccine,2009,28(1):162-170.
|
| [11] |
Mittendorf EA, Clifton GT, Holmes JP, et al. Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02[J].Cancer,2012,118(10):2594-2602.
|
| [12] |
Gates JD, Clifton GT, Benavides LC, et al. Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class ⅡHER2/neu (AE37) peptide[J]. Vaccine,2010,28(47):7476-7482.
|
| [13] |
Carmichael MG, Benavides LC, Holmes JP, et al. Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2)vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04[J].Cancer,2010,116(2):292-301.
|
| [14] |
Benavides LC, Sears AK, Gates JD, et al. Comparison of different HER2/neu vaccines in adjuvant breast cancer trials:implications for dosing of peptide vaccines[J]. Expert Rev Vaccines,2011,10(2):201-210.
|
| [15] |
Xu M, Kallinteris NL,von Hofe E. CD4+ T-cell activation for immunotherapy of malignancies using Ii-Key/MHC class Ⅱepitope hybrid vaccines [ J]. Vaccine, 2012, 30 (18 ):2805-2810.
|
| [16] |
Huang ZH, Shi L, Ma JW, et al. A totally synthetic, selfassembling, adjuvant-free MUC1 glycopeptide vaccine for cancer therapy [J]. J Am Chem Soc, 2012, 134 (21):8730-8733.
|
| [17] |
Pinkhasov J, Alvarez ML, Rigano MM, et al. Recombinant plant-expressed tumour-associated MUC1 peptide is immunogenic and capable of breaking tolerance in MUC1.Tg mice[J].Plant Biotechnol J,2011,9(9):991-1001.
|
| [18] |
Yuan S, Shi C, Liu L, et al. MUC1-based recombinant Bacillus Calmette-Guerin vaccines as candidates for breast cancer immunotherapy [J]. Expert Opin Biol Ther,2010,10(7):1037-1048.
|
| [19] |
Gao Y, Chen X, Gao W, et al. A new purification method for enhancing the immunogenicity of heat shock protein 70-peptide complexes[J].Oncol Rep,2012,28(6):1977-1983.
|
| [20] |
de la Torre A, Hernandez J, Ortiz R, et al. NGlycolylGM3/VSSP vaccine in metastatic breast cancer patients: results of phase Ⅰ/Ⅱa clinical trial[J].Breast Cancer (Auckl),2012,6:151-157.
|
| [21] |
Foy KC, Wygle RM, Miller MJ, et al. Peptide vaccines and peptidomimetics of EGFR (HER-1) ligand binding domain inhibit cancer cell growth in vitro and in vivo[J]. J Immunol,2013,191(1):217-227.
|
| [22] |
Hao S,Moyana T,Xiang J. Review:cancer immunotherapy by exosome-based vaccines [ J]. Cancer Biother Radiopharm,2007,22(5):692-703.
|
| [23] |
Wang L,Xie Y,Ahmed KA, et al. Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice [J]. Breast Cancer Res Treat,2013,140(2):273-284.
|
| [24] |
Wiedermann U, Wiltschke C, Jasinska J, et al. A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study [J]. Breast Cancer Res Treat,2010,119(3):673-683.
|
| [25] |
Morse MA, Wei J, Hartman Z, et al. Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo[J].Int J Cancer,2010,126(12):2893-2903.
|
| [26] |
Reisfeld RA. The tumor microenvironment: a target for combination therapy of breast cancer[J]. Crit Rev Oncog,2013,18(1-2):115-133.
|
| [27] |
Liu Z, Lv D, Liu S, et al. Alginic acid-coated chitosan nanoparticles loaded with legumain DNA vaccine:effect against breast cancer in mice[J].PLoS One,2013,8(4):e60190.
|
| [28] |
Liao D, Liu Z, Wrasidlo WJ, et al. Targeted therapeutic remodeling of the tumor microenvironment improves an HER-2 DNA vaccine and prevents recurrence in a murine breast cancer model[J].Cancer Res,2011,71(17):5688-5696.
|
| [29] |
Nakashima H, Fujisawa T, Husain SR, et al. Interleukin-13 receptor α2 DNA prime boost vaccine induces tumor immunity in murine tumor models[J].J Transl Med,2010,8:116.
|
| [30] |
Pakravan N, Langroudi L, Hajimoradi M, et al. Coadministration of GP96 and Her2/neu DNA vaccine in a Her2 breast cancer model[J].Cell Stress Chaperones,2010,15(6):977-984.
|
| [31] |
Nguyen-Hoai T, Baldenhofer G, Ahmed MS, et al. CCL19( ELC ) improves TH1-polarized immune responses and protective immunity in a murine Her2/neu DNA vaccination model[J].J Gene Med,2012,14(2):128-137.
|
| [32] |
Eccles S. c-erbB-2 as a target for immunotherapy[J]. Expert Opin Investig Drugs,1998,7(11):1879-1896.
|
| [33] |
程琳,彭媛,王殊.乳腺癌的生物治疗进展[J/CD]. 中华乳腺病杂志:电子版,2013,7(3):160-167.
|
| [34] |
Verma S, Miles D, Gianni L,et al. Trastuzumab emtansine for HER2-positive advanced breast cancer [J]. N Engl J Med,2012,367(19):1783-1791.
|
| [35] |
Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer[J].N Engl J Med,2011,365(14):1273-1283.
|
| [36] |
Pichinuk E, Benhar I, Jacobi O, et al. Antibody targeting of cell-bound MUC1 SEA domain kills tumor cells[J]. Cancer Res,2012,72(13):3324-3336.
|
| [37] |
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy[J].Nat Rev Cancer,2012,12(4):252-264.
|
| [38] |
尹令丝,黄俊琼.乳腺癌免疫治疗研究进展[J].临床医学工程,2013,20(2):259-260.
|